TY - JOUR
T1 - Staging and clean room
T2 - Constructs designed to facilitate transparency and reduce bias in comparative analyses of real-world data
AU - Muntner, Paul
AU - Hernandez, Rohini K.
AU - Kent, Shia T.
AU - Browning, James E.
AU - Gilbertson, David T.
AU - Hurwitz, Kathleen E.
AU - Jick, Susan S.
AU - Lai, Edward C.
AU - Lash, Timothy L.
AU - Monda, Keri L.
AU - Rothman, Kenneth J.
AU - Bradbury, Brian D.
AU - Brookhart, M. Alan
N1 - Publisher Copyright:
© 2024 John Wiley & Sons Ltd.
PY - 2024/3
Y1 - 2024/3
N2 - Purpose: We describe constructs designed to protect the integrity of the results from comparative analyses using real-world data (RWD): staging and clean room. Methods: Staging involves performing sequential preliminary analyses and evaluating the population size available and potential bias before conducting comparative analyses. A clean room involves restricted access to data and preliminary results, policies governing exploratory analyses and protocol deviations, and audit trail. These constructs are intended to allow decisions about protocol deviations, such as changes to design or model specification, to be made without knowledge of how they might affect subsequent analyses. We describe an example for implementing staging with a clean room. Results: Stage 1 may involve selecting a data source, developing and registering a protocol, establishing a clean room, and applying inclusion/exclusion criteria. Stage 2 may involve attempting to achieve covariate balance, often through propensity score models. Stage 3 may involve evaluating the presence of residual confounding using negative control outcomes. After each stage, check points may be implemented when a team of statisticians, epidemiologists and clinicians masked to how their decisions may affect study outcomes, reviews the results. This review team may be tasked with making recommendations for protocol deviations to address study precision or bias. They may recommend proceeding to the next stage, conducting additional analyses to address bias, or terminating the study. Stage 4 may involve conducting the comparative analyses. Conclusions: The staging and clean room constructs are intended to protect the integrity and enhance confidence in the results of analyses of RWD.
AB - Purpose: We describe constructs designed to protect the integrity of the results from comparative analyses using real-world data (RWD): staging and clean room. Methods: Staging involves performing sequential preliminary analyses and evaluating the population size available and potential bias before conducting comparative analyses. A clean room involves restricted access to data and preliminary results, policies governing exploratory analyses and protocol deviations, and audit trail. These constructs are intended to allow decisions about protocol deviations, such as changes to design or model specification, to be made without knowledge of how they might affect subsequent analyses. We describe an example for implementing staging with a clean room. Results: Stage 1 may involve selecting a data source, developing and registering a protocol, establishing a clean room, and applying inclusion/exclusion criteria. Stage 2 may involve attempting to achieve covariate balance, often through propensity score models. Stage 3 may involve evaluating the presence of residual confounding using negative control outcomes. After each stage, check points may be implemented when a team of statisticians, epidemiologists and clinicians masked to how their decisions may affect study outcomes, reviews the results. This review team may be tasked with making recommendations for protocol deviations to address study precision or bias. They may recommend proceeding to the next stage, conducting additional analyses to address bias, or terminating the study. Stage 4 may involve conducting the comparative analyses. Conclusions: The staging and clean room constructs are intended to protect the integrity and enhance confidence in the results of analyses of RWD.
UR - http://www.scopus.com/inward/record.url?scp=85186444681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186444681&partnerID=8YFLogxK
U2 - 10.1002/pds.5770
DO - 10.1002/pds.5770
M3 - Article
C2 - 38419140
AN - SCOPUS:85186444681
SN - 1053-8569
VL - 33
JO - Pharmacoepidemiology and drug safety
JF - Pharmacoepidemiology and drug safety
IS - 3
M1 - e5770
ER -